RUNX1 and acute myeloid leukemia: Interestingly, patients carrying both BCOR and RUNX1 mutations, both of which are members of CS-mutations, were particularly sensitive to JAK inhibitors, indicating that cooperation between CS-AML drivers may influence therapeutic strategies.